Heatwurx (NASDAQ:PCSA) Posts Earnings Results, Beats Expectations By $0.01 EPS

Heatwurx (NASDAQ:PCSA) issued its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01, FiscalAI reports.

Heatwurx Stock Performance

Shares of PCSA traded down $0.01 on Friday, reaching $0.31. The stock had a trading volume of 2,096,921 shares, compared to its average volume of 9,369,590. Heatwurx has a 12-month low of $0.15 and a 12-month high of $1.50. The firm has a market capitalization of $15.40 million, a price-to-earnings ratio of -0.13 and a beta of 1.45. The company has a 50-day simple moving average of $0.27 and a 200-day simple moving average of $0.25.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PCSA shares. Zacks Research cut shares of Heatwurx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research note on Wednesday, October 8th. Finally, HC Wainwright dropped their target price on shares of Heatwurx from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, September 2nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Heatwurx presently has an average rating of “Hold” and an average target price of $1.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.